UPDATE: Cowen Starts Ohr Pharmaceutical (OHRP) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Ohr Pharmaceutical (OHRP) Presents Additional Data from IMPACT Study; Shows Early Regression of SHRM in wet-AMD
March 2, 2015 7:34 AM ESTOhr Pharmaceutical (Nasdaq: OHRP) announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting which took place February 25-28th, in Scottsdale, Arizona. The new data show an early regression of subretinal hyper-reflective material (SHRM), an anatomic biomarker for the wet form of age-related macular degeneration (wet-AMD), which is consistent with the early gains in visual acuity previously reported from this study. The data were presented by Jason S. Slakter, MD, Chief Medical Officer at Ohr and Clinical Professor of Ophthalmology, NYU School of... More
Roth Capital Starts Ohr Pharmaceutical (OHRP) at Buy
February 26, 2015 7:10 AM ESTRoth Capital initiated coverage on Ohr Pharmaceutical (NASDAQ: OHRP) with a Buy rating and a price target of $30.00.
For an analyst ratings summary and ratings history on Ohr Pharmaceutical click here. For more ratings news on Ohr Pharmaceutical click here.
Shares of Ohr Pharmaceutical closed at $7.02 yesterday.
... More